Perspective on 177Lu-PSMA Therapy for metastatic castration-resistant prostate cancer

Journal of Nuclear Medicine

Volumn 57, Issue 7, 2016, Pages 1002-1003

  Kwekkeboom, Dik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; ENZALUTAMIDE; PENTETATE INDIUM IN 111; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN LU 177; RADIOPHARMACEUTICAL AGENT; TETRAXETAN J591 LU 177; UNCLASSIFIED DRUG; GLUTAMATE CARBOXYPEPTIDASE II; SINGLE HETEROCYCLIC RINGS;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG ABSORPTION; DRUG HALF LIFE; HUMAN; ISOTOPE LABELING; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; REVIEW; THERANOSTIC NANOMEDICINE; TREATMENT RESPONSE; XEROSTOMIA; MALE;

GLUTAMATE CARBOXYPEPTIDASE II; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84978397809     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.171363     Document Type: Review

References (8)

1. Recine F, Sternberg CN. Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. Transl Androl Urol. 2015; 4:355-364.
2. 177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26:2124-2130.
3. Strosberg J, Wolin E, Chasen B, et al. 177-Lu-dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: results of the phase III NETTER-1 trial. https://www.nanets.net/nanets-cd/2015/pdfs/C39.pdf. Accessed March 14, 2016.
4. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016; 57:1006-1013.
5. 177Lu-labeled J591 antibodies specific for prostate specific membrane antigen. J Nucl Med. 2005; 46:850-858.
6. 177Lu]lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015; 42:987-988.
7. 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015; 56:1169-1176.
8. 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015; 5: 114.